Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.
Zarski JP, Marcellin P, Leroy V, Trepo C, Samuel D, Ganne-Carrie N, Barange K, Canva V, Doffoel M, Cales P; Fédération nationale des Pôles de référence et des Réseaux Hépatites. Zarski JP, et al. Among authors: barange k. J Hepatol. 2006 Sep;45(3):355-60. doi: 10.1016/j.jhep.2006.03.007. Epub 2006 Apr 18. J Hepatol. 2006. PMID: 16750585
Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, Dussaix E, Voigt JJ, Selves J, Barange K, Puel J, Pascal JP. Payen JL, et al. Among authors: barange k. Hepatology. 1998 Dec;28(6):1680-6. doi: 10.1002/hep.510280631. Hepatology. 1998. PMID: 9828235 Clinical Trial.
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study.
Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, Trimoulet P, Couzigou P, Cointe D, Chaput C, Henquell C, Abergel A, Pawlotsky JM, Hezode C, Coudé M, Blanchi A, Alain S, Loustaud-Ratti V, Chevallier P, Trepo C, Gerolami V, Portal I, Halfon P, Bourlière M, Bogard M, Plouvier E, Laffont C, Agius G, Silvain C, Brodard V, Thiefin G, Buffet-Janvresse C, Riachi G, Grattard F, Bourlet T, Stoll-Keller F, Doffoel M, Izopet J, Barange K, Martinot-Peignoux M, Branger M, Rosenberg A, Sogni P, Chaix ML, Pol S, Thibault V, Opolon P, Charrois A, Serfaty L, Fouqueray B, Grange JD, Lefrère JJ, Lunel-Fabiani F. Payan C, et al. Among authors: barange k. J Viral Hepat. 2005 Jul;12(4):405-13. doi: 10.1111/j.1365-2893.2005.00605.x. J Viral Hepat. 2005. PMID: 15985012
Efficacy and safety of lactosaminated human serum albumin-adenine arabinoside monophosphate in chronic hepatitis B patients non-responders to interferon therapy: a randomised clinical trial.
Zarski JP, Barange K, Souvignet C, Bertini M, Marcellin P, Tran A, Deugnier Y, Couzigou P, Plages A, Ambroise-Thomas P. Zarski JP, et al. Among authors: barange k. J Hepatol. 2001 Mar;34(3):486-8. doi: 10.1016/s0168-8278(01)00018-6. J Hepatol. 2001. PMID: 11322216 Clinical Trial. No abstract available.
Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Lacombe JM, Esterle L, Dorival C, Bourlière M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L; ANRS CO13 HEPAVIH, ANRS CO22 HEPATHER Cohorts Study Groups; Martinez V. Chalouni M, et al. HIV Med. 2021 Nov;22(10):924-935. doi: 10.1111/hiv.13153. Epub 2021 Aug 17. HIV Med. 2021. PMID: 34402547 Free article.
Reinforced regimen of interferon alfa-2a reduces the incidence of cirrhosis in patients with chronic hepatitis C: a multicentre randomised trial. Multicentre GER-CYT-04 Group.
Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Naveau S, Bailly F, Chaumet-Riffaud P, Chastang C. Degos F, et al. Among authors: barange k. J Hepatol. 1998 Aug;29(2):224-32. doi: 10.1016/s0168-8278(98)80007-x. J Hepatol. 1998. PMID: 9722203 Clinical Trial.
Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.
Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C; French multicenter study group. Abergel A, et al. Among authors: barange k. J Viral Hepat. 2006 Dec;13(12):811-20. doi: 10.1111/j.1365-2893.2006.00768.x. J Viral Hepat. 2006. PMID: 17109680 Clinical Trial.
Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
Naveau S, Balian A, Degos F, Daurat V, Chevret S, Gayno S, Bastie A, Riachi G, Bartolomei-Portal I, Barange K, Moussalli J, Bailly F, Chaumet-Riffaud P, Emilie D. Naveau S, et al. Among authors: barange k. J Hepatol. 1999 Oct;31(4):612-7. doi: 10.1016/s0168-8278(99)80339-0. J Hepatol. 1999. PMID: 10551383 Clinical Trial.
Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M, Pol S, Sogni P, Fontaine H, Lacombe K, Marc-Lacombe J, Esterle L, Dorival C, Bourlière M, Bani-Sadr F, de Ledinghen V, Zucman D, Larrey D, Salmon D, Carrat F, Wittkop L; ANRS CO13 HEPAVIH and ANRS CO22 HEPATHER cohort study groups. Chalouni M, et al. J Hepatol. 2021 Jan;74(1):37-47. doi: 10.1016/j.jhep.2020.08.008. Epub 2020 Aug 14. J Hepatol. 2021. PMID: 32798585 Free article.
87 results